Floatz logo

Inno-206

Recurrent Malignant Mesothelioma

Mayo ClinicEarly Phase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

29 Active assets in the Recurrent Malignant Mesothelioma cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
Dr Jean Yannis PERENTES
Phase 2BB
Inno-206
Mayo Clinic
Phase 2BB
Cyclophosphamide
M.D. Anderson Cancer Center
Phase 2BB
Sargramostim
Memorial Sloan Kettering Cancer Center
Phase 2BB
TAMOXIFEN
Ottawa Regional Cancer Centre
Phase 2B

View all 50 →

Same molecule, other indications

Inno-206 is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →
plasma cell myelomaDormant
BBB
Indicative ·
77 / 100
View asset →
Recurrent Adult Acute Lymphoblastic LeukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →